Delisting risk
ARTL · NASDAQ · Biotechnology

Artelo Biosciences

Develops cannabinoid and fatty-acid-binding-protein drug candidates for cancer supportive care and pain.

$0.7125
After-hours close+0.05 (+7.53%)
At close$0.6626(+0.24%)
DateEstimateReportedSurprise
Nov 2026−$0.78
Aug 2026−$0.72−$0.89−23.6%
May 2026−$0.78−$4.00−412.8%
Feb 2026−$4.71−$6.66−41.4%
Nov 2025−$0.82−$3.97−384.1%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Jan 2022
Nov 2021
Jul 2021
Apr 2021
Jan 2021
Nov 2020
Jul 2020
Apr 2020
Jan 2020
Nov 2019
Jul 2019
Apr 2019
Jan 2019
Nov 2018
Jul 2018
Apr 2018
Jan 2018
Nov 2017
Jul 2017
Apr 2017
Jan 2017
Nov 2016
Jul 2016
Apr 2016
Jan 2016
Dec 2015
Jul 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 17, 2026−$0.78
Aug 12, 2026−$0.72−$0.89−23.6%
May 14, 2026−$0.78−$4.00−412.8%
Feb 24, 2026−$4.71−$6.66−41.4%
Nov 12, 2025−$0.82−$3.97−384.1%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 13, 2025
Mar 3, 2025
Nov 12, 2024
Aug 13, 2024
May 13, 2024
Mar 25, 2024
Nov 13, 2023
Aug 10, 2023
May 11, 2023
Mar 31, 2023
Nov 8, 2022
Aug 9, 2022
May 12, 2022
Jan 12, 2022
Nov 29, 2021
Jul 12, 2021
Apr 13, 2021
Jan 14, 2021
Nov 4, 2020
Jul 13, 2020
Apr 14, 2020
Jan 14, 2020
Nov 25, 2019
Jul 15, 2019
Apr 15, 2019
Jan 14, 2019
Nov 29, 2018
Jul 13, 2018
Apr 16, 2018
Jan 16, 2018
Nov 29, 2017
Jul 21, 2017
Apr 14, 2017
Jan 10, 2017
Nov 29, 2016
Jul 5, 2016
Apr 1, 2016
Jan 14, 2016
Dec 11, 2015
Jul 15, 2015